Alopecia areata. A follow-up investigation of outpatient material.

L, Gip; Lodin, A; Molin, L

doi:10.2340/0001555549180188

Cited by 58 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[36].Current data propose 34%-50% of patients recover within 1 year, while 14%-25% of patients will progress to AT or AU, at which point patients rarely fully recover. [37]…”

Section: Chemotherapy and Hair Lossmentioning

confidence: 99%

A Brief Study on Alopecia Areata

Gupta,

Singh,

Padiyar

2024

Int. J. Res. Publ. Rev.

View full text Add to dashboard Cite

Alopecia areata (AA) is a complex autoimmune condition that causes nonscarring hair loss of scalp or/and body.It commonly presents with sharply demarcated round patches of hair loss and may present at any stage of life. Atopy and autoimmune thyroiditis are most normal related conditions. Treatment is mainly focused to contain the disease activity. Current medicines and treatments including topical, systemic and injectable mediations show different reaction and persistent relapses reflecting the neglected clinical need. The etiology of AA is complicated and includes genetic and environmental factors, with significant advancements in genetic research occurring in recent years. This disease commonly presents as round or patchy uncovered spots without scarring.Treatment choices for alopecia areata include topical corticosteroids, immunotherapy, and minoxidil, among others. In some cases, it can also affect the nails, making them weak or pitted. At times, the condition might advance to total hair loss on the scalp (alopecia totalis) or even the whole body (alopecia universalis).

show abstract

“…[36].Current data propose 34%-50% of patients recover within 1 year, while 14%-25% of patients will progress to AT or AU, at which point patients rarely fully recover. [37]…”

Section: Chemotherapy and Hair Lossmentioning

confidence: 99%

A Brief Study on Alopecia Areata

Gupta,

Singh,

Padiyar

2024

Int. J. Res. Publ. Rev.

View full text Add to dashboard Cite

show abstract

Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population

et al. 2023

View full text Add to dashboard Cite

ImportanceAlopecia areata (AA) is characterized by nonscarring hair loss of the scalp, face, and/or body. Alopecia totalis (AT) and alopecia universalis (AU) involve complete loss of the scalp and body hair, respectively. The epidemiology of AA in the US remains unclear, having previously been extrapolated from older studies that were limited to specific geographic areas or clinical settings, or from self-reported data.ObjectiveTo estimate the annual prevalence and incidence of AA and AT and/or AU (AT/AU) in the US.Design, Setting, and ParticipantsThis retrospective, population-based cohort study was conducted from January 2016 to December 2019 and included enrollees in the IBM MarketScan Commercial Claims and Encounters and Medicare Supplemental databases and their dependents, with plan enrollment during each study calendar year and the year prior.ExposuresPrevalent cases were identified by 1 or more claims for AA or AT/AU (International Statistical Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] codes L63.x, L63.0, L63.1) during each year of interest or the year prior. Incident cases were identified by 1 or more claims for AA or AT/AU during a specific year and no diagnosis the year prior.Main Outcomes and MeasuresAnnual incidence and prevalence rates were calculated and stratified by age, sex, and region. National employer-sponsored insurance population estimates were obtained using population-based weights.ResultsAmong eligible patients (2016: n = 18 368 [mean (SD) age, 40.6 (17.9) years; 12 295 women (66.9%)]; 2017: n = 14 372 [mean (SD) age, 39.6 (17.7) years; 9195 women (64.0%)]; 2018: n = 14 231 [mean (SD) age, 38.9 (17.3) years; 8998 women (63.2%)]; 2019: n = 13 455 [mean (SD) age, 39.1 (17.4) years; 8322 women (61.9%)]), AA prevalence increased from 0.199% (95% CI, 0.198%-0.200%) in 2016 to 0.222% (95% CI, 0.221%-0.223%) in 2019. Roughly 5% to 10% of prevalent and incident cases of AA were AT/AU. The prevalence of AT/AU increased from 0.012% (95% CI, 0.012%-0.013%) to 0.019% (95% CI, 0.018%-0.019%) from 2016 to 2019. Incidence of AA per 100 000 person-years ranged from 87.39 (95% CI, 86.84-87.96) in 2017 to 92.90 (95% CI, 92.35-93.45) in 2019. Incidence of AT/AU ranged from 7.09 (95% CI, 6.94-7.25) in 2017 to 8.92 (95% CI, 8.75-9.09) in 2016. Prevalence and incidence of AA and AT/AU were higher among female vs male individuals, adults vs children and adolescents, and in the Northeast vs other regions.Conclusions and RelevanceThe results of this cohort study suggest that these recent AA prevalence and incidence estimates could help improve current understanding of the disease burden. Further research is warranted to elucidate subpopulation differences and trends in AA in the broader US population.

show abstract